A method for determining the endogenous urinary excretion levels of both
3-hydroxyproline and
4-hydroxyproline that may be useful for
cancer screening of the general population and at the workplace is evaluated in this report. The excretion levels of
3-hydroxyproline and 4-hydroxproline were estimated in 97 patients with
cancer and in 99 patients with various nonmalignant diseases and were compared with those of 211 healthy persons. Measurable
3-hydroxyproline peaks (by
amino acid autoanalyzer) were absent from 93 samples from 211 healthy persons (44%), 50 of 99 patients with nonmalignant disease (50%), and 10 of 96 patients with
cancer (10%). The levels of both
3-hydroxyproline and
4-hydroxyproline in
cancer patients were significantly higher than those in healthy persons (p < 0.001 and p < 0.01, respectively) and those in patients with nonmalignant diseases (p < 0.05 and p < 0.01, respectively).
Cancer patients were classified into three groups according to grade of
cancer growth and invasion. The sensitivity of
3-hydroxyproline was 44% and higher than that of
4-hydroxyproline for the detection of stage II
cancers (no distant
metastasis); the sensitivities of both hydroxyprolines for the detection of stage I (very early
cancer) were low. The specificity of these assays for healthy persons and patients with nonmalignant disease was 96% and 92% for
3-hydroxyproline, and 97% and 79% for
4-hydroxyproline, respectively. Urinary
3-hydroxyproline level should be further investigated as a
cancer screening method for healthy persons in the community or the workplace, but appears unlikely to detect many
cancers in the earliest stages.